Antiseizure Medications

The antiseizure medications (ASMs, formerly "antiepileptic drugs") are a sprawling pharmacopeia that intimidates students and humbles experts. The trick to mastering them is to stop memorizing an alphabetical list of drugs and instead group them by mechanism of action. Almost every ASM works by one of a few strategies: damping down excitatory neuronal firing (block voltage-gated sodium or calcium channels), boosting inhibition (enhance GABA), or modulating synaptic vesicle release (the SV2A drugs). A handful are deliberately promiscuous, hitting several targets at once — these are the broad-spectrum agents that work across the widest range of seizure types. Once you anchor each drug to its mechanism, two clinically vital things fall into place: which seizure types it treats, and which adverse effects to anticipate. What follows is an accuracy-first tour organized by target, with the high-yield pearls a clinician actually needs at the bedside.

Sodium-channel blockers

These drugs bind preferentially to the inactivated state of the voltage-gated sodium channel, prolonging its refractory period and selectively suppressing the rapid, repetitive firing that drives a seizure focus. As a class they are the workhorses for focal (partial) seizures and focal-to-bilateral tonic-clonic seizures.

• Phenytoin and its water-soluble prodrug fosphenytoin (preferred for IV/IM loading because it avoids phenytoin's propylene glycol vehicle).
• Carbamazepine and its keto-analog oxcarbazepine (and oxcarbazepine's active metabolite delivered as eslicarbazepine).
• Lamotrigine — a sodium-channel blocker that is nonetheless broad-spectrum in practice (see below).
• Lacosamide — enhances the slow inactivation of the sodium channel, a mechanistically distinct twist on the same target.
• Valproate and topiramate have sodium-channel blockade as one of several mechanisms, which is part of why they are broad-spectrum.

Pearl: Sodium-channel blockade is excellent for focal seizures but is exactly the wrong move in many generalized epilepsies — see the spectrum pearl below.

Calcium-channel modulators

• Ethosuximide blocks T-type calcium channels in thalamic neurons — the oscillatory circuit that generates the 3-Hz spike-and-wave of absence seizures. It is the drug of choice for childhood absence epilepsy (with valproate as the broad-spectrum alternative), and it is essentially useless against other seizure types.
• Gabapentin and pregabalin bind the α2δ subunit of voltage-gated (high-voltage-activated) calcium channels, reducing presynaptic calcium influx and excitatory neurotransmitter release. Both are narrow-spectrum adjuncts for focal seizures and are used heavily for neuropathic pain; gabapentin's erratic, saturable absorption limits high-dose reliability.

Pearl: Despite the names, neither gabapentin nor pregabalin acts on the GABA receptor — they are calcium-channel α2δ ligands. The "GABA" in the name is a historical misnomer.

GABA-ergic drugs (enhance inhibition)

GABA is the brain's principal inhibitory neurotransmitter; these agents raise inhibitory tone by several different routes.

• Benzodiazepines (lorazepam, diazepam, midazolam, clonazepam, clobazam) bind an allosteric site on the GABA-A receptor and increase the frequency of chloride-channel opening. Fast-acting — the first-line abortive agents in status epilepticus.
• Barbiturates (phenobarbital, and the prodrug primidone) also potentiate GABA-A but increase the duration of channel opening; at high concentrations they can open the channel directly. Effective and cheap, but sedating and a potent enzyme inducer.
• Vigabatrin is an irreversible inhibitor of GABA-transaminase, the enzyme that degrades GABA, so synaptic GABA accumulates. Reserved for refractory cases and infantile spasms because of irreversible, often asymptomatic peripheral visual-field constriction.
• Tiagabine blocks the GAT-1 GABA reuptake transporter, prolonging GABA's action in the synaptic cleft.

Synaptic vesicle protein 2A (SV2A)

• Levetiracetam and brivaracetam bind SV2A, a synaptic vesicle glycoprotein, modulating neurotransmitter release through a mechanism distinct from every other class. Both are broad-spectrum, have a clean drug-interaction profile, and levetiracetam needs no titration to a starting therapeutic dose — qualities that have made it a go-to first-line and IV agent.

Broad-spectrum agents (multiple mechanisms)

Several drugs hit more than one target, which broadens the range of seizure types they cover.

• Valproate — the prototypical broad-spectrum ASM: it works on focal, generalized tonic-clonic, absence, and myoclonic seizures. Mechanisms include sodium-channel blockade, augmentation of GABA, and probable T-type calcium effects.
• Topiramate — sodium-channel blockade, GABA-A enhancement, AMPA/kainate glutamate-receptor antagonism, and carbonic-anhydrase inhibition.
• Zonisamide — sodium- and T-type calcium-channel blockade (a sulfonamide, like topiramate, sharing some of its adverse effects).
• Lamotrigine — although mechanistically a sodium-channel blocker, it behaves clinically as a broad-spectrum agent and is a mainstay in generalized epilepsy. Caveat: lamotrigine can worsen myoclonic seizures in some patients, especially in juvenile myoclonic epilepsy (JME); in syndromes with prominent myoclonus, levetiracetam or valproate (with attention to reproductive/teratogenic risk) are often preferred.

The spectrum pearl (do not skip this)

This is one of the highest-yield, most clinically consequential facts in all of epilepsy pharmacology:

• Narrow-spectrum sodium-channel blockers — carbamazepine, oxcarbazepine, phenytoin — and gabapentin can WORSEN absence and myoclonic seizures. Prescribing carbamazepine to a patient whose "focal" event is actually juvenile myoclonic epilepsy can aggravate the very condition you are trying to treat.
• In generalized / idiopathic (genetic) epilepsies, reach for a broad-spectrum agent: valproate, levetiracetam, lamotrigine, or topiramate.
• The corollary: when the syndrome is uncertain, a broad-spectrum drug is the safer empiric choice because it will not unmask hidden generalized seizures.

Key adverse effects and clinical pearls

• Phenytoin — follows nonlinear (zero-order, saturable) kinetics, so small dose increases can produce large jumps in level. Chronic effects: gingival hyperplasia, hirsutism, coarsening of facial features; toxicity produces cerebellar signs and nystagmus (and at extremes, ataxia and confusion). It is a potent CYP450 inducer. IV infusion can cause purple glove syndrome (limb edema, discoloration, and pain), one reason fosphenytoin is preferred parenterally.
• Carbamazepine — classic causes of hyponatremia (SIADH-like), and rare but serious hematologic toxicity (aplastic anemia, agranulocytosis). Risk of Stevens-Johnson syndrome / toxic epidermal necrolysis is strongly linked to the HLA-B*15:02 allele — screen before starting in patients of at-risk Asian ancestry (Han Chinese, Thai, and other Southeast Asian populations). It is a CYP inducer and notably auto-induces its own metabolism, so levels drift down over the first weeks.
• Valproate — highly teratogenic: it carries the greatest risk among ASMs for neural tube defects and is associated with lower IQ and neurodevelopmental impairment in exposed offspring, so it is avoided wherever possible in people of childbearing potential. Other toxicities: hepatotoxicity (idiosyncratic, can be fatal, highest risk in young children), hyperammonemia (which can cause encephalopathy even with normal LFTs), pancreatitis, tremor, weight gain, and thrombocytopenia. Pharmacologically it is an enzyme inhibitor (the opposite of phenytoin and carbamazepine).
• Lamotrigine — must be titrated slowly to minimize the risk of serious rash and Stevens-Johnson syndrome. The titration is even slower when combined with valproate, which inhibits lamotrigine's glucuronidation and roughly doubles its level; conversely, enzyme inducers lower it.
• Levetiracetam — generally well tolerated with minimal drug interactions, but causes irritability, mood changes, and behavioral / psychiatric effects in a meaningful minority (pyridoxine supplementation is sometimes tried). Brivaracetam shares the mechanism with a somewhat milder behavioral profile.
• Topiramate — cognitive slowing and word-finding difficulty ("dopamax"), weight loss, kidney stones, metabolic acidosis (carbonic-anhydrase inhibition), acute angle-closure glaucoma, paresthesias, and oligohidrosis (decreased sweating, with risk of hyperthermia, especially in children).
• Lacosamide — can cause dose-dependent PR-interval prolongation; use caution with conduction disease or other PR-prolonging drugs.
• Phenobarbital / barbiturates — sedation, cognitive and behavioral effects (paradoxical hyperactivity in children), and potent enzyme induction.
• Vigabatrin — irreversible, often permanent peripheral visual-field constriction requiring periodic perimetry.

Status epilepticus (brief)

The general sequence for convulsive status epilepticus:

• First-line (abortive): a benzodiazepine — IV lorazepam, IM midazolam, or IV/rectal diazepam.
• Second-line (urgent control): an IV antiseizure agent — levetiracetam, valproate, or fosphenytoin (the landmark comparison found these three roughly equivalent for benzodiazepine-refractory status).
• Refractory status: escalate to continuous IV anesthetic infusions (midazolam, propofol, or pentobarbital) with EEG monitoring.

Quick-reference table

A word of caution

This page covers mechanisms and the highest-yield adverse effects — it is not a dosing reference. Actual dosing, titration schedules, therapeutic drug monitoring, renal/hepatic adjustment, and drug-interaction management must come from current prescribing information and pharmacy resources. Choice of agent always depends on the specific seizure type and epilepsy syndrome, age, sex and reproductive plans, comorbidities, and the patient's other medications. Confirm the diagnosis and the syndrome before committing to a narrow-spectrum drug.